1st Advances in Rare Bone Diseases Conference

描述（由申请人提供）：R13支持的这一请求将在一定程度上提供举办罕见骨病科学和患者互动会议的手段。会议将于2008年10月23日至24日在美国国立卫生研究院贝塞斯达校区举行，题目为“罕见骨病的第一次进展（ARBD-1）”。会议的目的是（1）检查与一系列遗传性骨病相关的基础，转化和临床研究的最新进展（2）了解科学的最新进展如何应用于骨生物学和临床骨学领域（3）允许选定的学员和初级教师向该领域的专家介绍他们的相关工作，（4）让感兴趣的非专业观众与这些骨病的科学和医学专家以及涉及骨病和孤儿病的制药行业互动;（5）建立新的理解领域和研究与治疗需求。受邀专家和与会者将代表不同的学科，包括遗传学，分子生物学，纳米生物学，内分泌学，风湿病学，肾脏病学，胃肠病学，营养学，运动生理学，骨科，放射学，人类学，免疫学，细胞生物学和生物力学工程等。会议联合主任和16位已成立的国际骨研究者（作为计划委员会）制定了为期2天的科学计划，其中包括总体全体会议讲座，指导最新技术演示，邀请美国食品药品监督管理局的讲座，涉及罕见骨病代表的孤儿疾病的制药行业，以及针对7种特定疾病实体的热门话题讨论。国家关节炎、肌肉骨骼和皮肤疾病研究所与罕见疾病办公室沿着已经批准了这一申请，并批准了其提交。R13支持的这一请求将在一定程度上提供举办罕见骨病科学和患者互动会议的手段。会议的标题为“罕见骨病的第一进展（ARBD-1）”，将于2008年10月23日至24日在NIH校园贝塞斯达举行。会议的主要目标是提供有关影响骨骼的罕见疾病的最新研究和临床信息，并扩大和进一步发展研究界与致力于为这些疾病患者服务的非专业组织之间的伙伴关系。FDA和企业科学家都将参与此次交流。此外，本次会议将促进生物医学研究界的最新技术转移到罕见骨病领域的研究人员。

DESCRIPTION (provided by applicant): This request for R13 support will provide, in part, the means to hold a scientific and patient-interactive conference on rare bone diseases. It will be entitled "1st Advances in Rare Bone Diseases, (ARBD-1)" and will occur in Bethesda on the NIH Campus on 23- 24 October 2008. The objectives of the conference are (1) to examine the latest advances in basic, translational, and clinical research relating to a series of genetic bone diseases (2) to understand how recent advances in science may be applied to the areas of bone biology and clinical osteology (3) to allow selected trainees and junior faculty to present their relevant work to an audience of experts in the field, (4) to have an interested lay audience interact with scientific and medical experts in these bone diseases, and the pharmaceutical industry involved in bone and orphan diseases and (5) to forge new areas of understanding and need for research and therapeutics. Invited experts and attendees will represent diverse disciplines that include genetics, molecular biology, nanobiology, endocrinology, rheumatology, nephrology, gastroenterology, nutrition, exercise physiology, orthopedics, radiology, anthropology, immunology, cell biology, and biomechanical engineering, among others. The conference co-directors, and sixteen established, international bone investigators serving as the Program Committee have developed a 2-day scientific program that includes overarching plenary lectures, directed state of the art presentations, invited lectures from the Food and Drug Administration, the pharmaceutical industry involved in orphan diseases represented by rare bone diseases, and Hot Topic discussions for seven specific disease entities. The National Institute for Arthritis, Musculoskeletal and Skin Diseases, along with the Office of Rare Diseases, has endorsed this application and granted permission for its submission. This request for R13 support will provide, in part, the means to hold a scientific and patient-interactive conference on rare bone diseases. It will be entitled "1st Advances in Rare Bone Diseases, (ARBD-1)" and will occur in Bethesda on the NIH Campus on 23- 24 October 2008. The key objectives of the conference are to provide the latest research and clinical information on rare diseases affecting the skeleton and to extend and further develop partnerships between the research community and lay organizations dedicated to serving patients with these diseases. Both the FDA and corporate scientists will participate in this exchange. Additionally, this conference will facilitate transfer of the latest technology from the biomedical research community to investigators working in the rare bone disease field.